New hope for glioblastoma? drug combo trial launches

NCT ID NCT05986851

Ongoing Disease control Sponsor: Cantex Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests the drug azeliragon, taken as a capsule, together with radiation therapy for people with a specific type of glioblastoma (a fast-growing brain cancer). The study includes 30 participants whose tumors lack a certain DNA marker (MGMT unmethylated). The goal is to see if the combination is safe and can slow cancer growth or improve survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Azeliragon (oral capsule)
What this could lead to: If successful, this could point toward a new treatment option for a hard-to-treat form of glioblastoma, potentially slowing cancer growth and extending survival.
What could go wrong: This is a small, early-phase trial with only 30 participants, so results may not apply widely. The drug may not prove effective or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma IDH-wildtype glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA

Contacts and locations

Locations

Corewell Health

Royal Oak, Michigan, 48073, United States
Lenox Hill Hospital

New York, New York, 10021, United States
Miami Cancer Institute - Baptist Health

Miami, Florida, 33176, United States
The University of Oklahoma Health Science Center

Oklahoma City, Oklahoma, 73104, United States
University of Colorado Anschutz Medical Campus

Aurora, Colorado, 80045, United States
University of Utah Health Huntsman Cancer Center

Salt Lake City, Utah, 84112, United States
University of Washington

Seattle, Washington, 98109, United States
Washington University in St. Louis

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.